Schedule 13D ownership disclosure

CAMP4 Therapeutics Corp.

Common Stock, par value $0.0001 per share · CUSIP: 13463J101

Event date: 2025-09-09

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Polaris Management Co. VII, L.L.C.Reported CIK 0001678203

    Shares: 3,023,161 · Class: 6.4%

  • Polaris Partners VII, L.P.Reported CIK 0001611189

    Shares: 2,825,500 · Class: 6.0%

  • Polaris Entrepreneurs' Fund VII, L.P.Reported CIK 0001615991

    Shares: 197,661 · Class: 0.4%

  • Polaris Partners GP X, L.L.C.Reported CIK 0001910575

    Shares: 909,090 · Class: 1.9%

  • Polaris Partners X, L.P.Reported CIK 0001910577

    Shares: 909,090 · Class: 1.9%

  • Amir NashatReported CIK 0001575843

    Shares: 3,932,251 · Class: 8.4%

  • Brian CheeReported CIK 0001295675

    Shares: 909,090 · Class: 1.9%

  • Amy SchulmanReported CIK 0001438226

    Shares: 909,090 · Class: 1.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-25-201410
Form type
SCHEDULE 13D/A
Filer
Camp4 Therapeutics Corp
CIK
CIK 1736730
Filed
Sep 11, 2025
Reporting period
Sep 09, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub